Magnetic Resonance–guided Focused Ultrasound of Uterine Leiomyomas: Review of a 12-month Outcome of 130 Clinical Patients

Abstract

Purpose To assess 12-month outcomes and safety of clinical magnetic resonance (MR)–guided focused ultrasound (US) treatments of uterine leiomyomas. Materials and Methods Between March 2005 and December 2009, 150 women with symptomatic uterine leiomyomas were clinically treated with MR-guided focused US at a single institution; 130 patients completed treatment and agreed to have their data used for research purposes. Patients were followed through retrospective review of medical records and phone interviews conducted at 3-, 6-, and 12-month intervals after treatment to assess additional procedures and symptom relief. Outcome measures and treatment complications were analyzed for possible correlations with the appearance of the tumors on T2-weighted imaging. Results The cumulative incidence of additional tumor-related treatments 12 months after MR-guided focused US was 7.4% by the Kaplan–Meier method. At 3-, 6-, and 12-month follow-up, 86% (90 of 105), 93% (92 of 99), and 88% (78 of 89) of patients reported relief of symptoms, respectively. No statistically significant correlation between tumor appearance on T2-weighted imaging and 12-month outcome was found. Treatment-related complications were observed in 17 patients (13.1%): 16 patients had minor complications and one had a major complication (deep vein thrombosis). All complications were resolved within the 12-month follow-up period. Conclusions MR-guided focused US is a noninvasive treatment option that can be used to effectively and safely treat uterine leiomyomas and delivers significant and lasting symptom relief for at least 12 months. The incidence of additional treatment during this time period is comparable with those in previous reports of uterine artery embolization.

HIFU for Palliative Treatment of Pancreatic Cancer

“…Motion artifact due to breathing and heartbeat is also a concern in clinical setting. The only US FDAapproved HIFU device available for clinical therapy utilizes MR thermometry during treatment of uterine fibroids (39,41).…”

A histological evaluation and in vivo assessment of intratumoral near infrared photothermal nanotherapy-induced tumor regression

“…A variety of local, intratumoral therapies have been developed to provide advantages over surgery and chemo-radiation, that include minimal invasiveness, minimal side effects, and shorter hospitalizations. [1][2][3][4] These therapies are based on different physical mechanisms and ablation techniques including microwave, [5][6][7] focused ultrasound, [8][9][10] radiofrequency, 11,12 and cryoablation [13][14][15] therapies. The disadvantages of these therapies include limited specificity, limited delivery, and tumor recurrence.…”

Safety of MR-guided focused ultrasound treatment of pedunculated subserosal uterine leiomyomas

“…Our institution has been performing MRgFUS ablation of uterine leiomyomas in patients with clinical indications for treatment since March 2005 [10][11][12][13]. A database of all treated patients has been kept for retrospective research purposes such as this one, with approval by the Mayo Clinic Institutional Review Board.…”